This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

abatacept (Orencia®)

Reference No. 2232

Publication date:

Appraisal information

abatacept (Orencia®) 125 mg solution for injection
abatacept (Orencia®) 50 mg solution for injection
abatacept (Orencia®) 87.5 mg solution for injection

Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 17/07/2019

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, abatacept (Orencia®) cannot be endorsed for use within NHS Wales in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients from 2 years of age to < 6 years of age and older who have had an insufficient response to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one tumour necrosis factor (TNF) inhibitor
Statement of Advice (SOA)